Replicate NfL analysis in phase 3 multiple sclerosis - simvastatin trial 2 (MS-STAT2 trial). Develop novel biomarkers for neuroprotection independent of neuroinflammation. Explore mechanisms of simvastatin's effects on brain atrophy. This evidence concerns the gene STAT2 and multiple sclerosis.